IQVIA Holdings Inc. $IQV Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 80.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,301 shares of the medical research company’s stock after selling 22,429 shares during the period. CenterBook Partners LP’s holdings in IQVIA were worth $1,195,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Ameliora Wealth Management Ltd. purchased a new position in IQVIA in the fourth quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA during the 4th quarter worth about $27,000. Measured Wealth Private Client Group LLC acquired a new position in shares of IQVIA during the 3rd quarter worth about $30,000. Activest Wealth Management increased its holdings in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of IQVIA in the 4th quarter valued at about $35,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent analyst reports. Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Truist Financial reduced their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Down 2.1%

Shares of NYSE:IQV opened at $182.28 on Thursday. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market cap of $30.42 billion, a P/E ratio of 22.59, a P/E/G ratio of 1.60 and a beta of 1.21. The firm has a fifty day moving average price of $173.18 and a 200 day moving average price of $194.08.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.